HER-2阳性炎性乳腺癌的靶向治疗进展  

Progress in molecular targeted therapy for HER-2 positive inflammatory breast cancer

作　　者：汪泽兴[1] 管晓翔[1] 

机构地区：[1]南京大学医学院临床学院南京军区南京总医院肿瘤内科,南京210002

出　　处：《临床肿瘤学杂志》2013年第1期74-77,共4页Chinese Clinical Oncology

基　　金：国家自然科学基金资助项目(81141094;81272252);江苏省自然科学基金资助项目(BK2011656)

摘　　要：原癌基因人类表皮生长因子受体2(HER-2)阳性炎性乳腺癌是指HER-2过表达或扩增的炎性乳腺癌。临床上以乳房表面皮肤呈炎性改变而没有溃疡形成、局部及全身快速进展为特点,表现出更高的侵袭性。尽管炎性乳腺癌预后差,但新辅助化疗、手术及放疗等多学科综合治疗,尤其是分子靶向治疗显著改变了本病的自然进程。本文就近年来HER-2阳性炎性乳腺癌的分子靶向治疗进展作一综述。Human epidermal growth factor receptor-2 （ HER-2 ） positive inflammatory breast cancer is a very aggressive type of inflammatory breast cancer（IBC） with HER-2 over-expression or amplified. Clinically, such cancer is more aggressive and characterized by rapid local and systemic progression and overlying skin inflammation or discoloration without ulceration. With poor prognosis, but, combinations of neo-adjuvant systemic chemotherapy, surgery and radiation therapy, especially molecular targeted therapy can drastically alter the natural course of this disease. This article reviews the progress in molecular targeted therapy for HER-2 positive IBC in recent years.

关 键 词：HER-2 炎性乳腺癌 分子靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]